Biogen's latest “blockbuster drug” could generate billions

By Admin
Spinraza is the worlds first approved treatment for spinal muscular atrophy and could drive sustained growth for the drug manufacturer for years to come...

Spinraza is the world’s first approved treatment for spinal muscular atrophy and could drive sustained growth for the drug manufacturer for years to come.

Industry experts believe that Biogen Inc could have another so-called “blockbuster drug” on their hands as sales of Spinraza, which is the first approved treatment for spinal muscular atrophy, blew analysts’ predictions out of the water.

Sales of the new product have driven a strong first quarter performance for the company and it’s believed that the new drug could drive future growth for Biogen – and that’s despite it having a price tag of $750,000 for the first year and $375,000 annually, which makes it one of the most expensive prescription drugs in the country.

Spinraza is the first treatment of its kind and was approved by the U.S. Food and Drug Administration in December to be used to combat SMA, which is the leading genetic killer of children.

Analysts have projected that Spinraza could generate between $1.5 billion and $2 billion in sales worldwide within five years, if regulators around the globe approve its sale.

The new product generated sales of $47 million, around three times what was estimated during a survey last week by financial firm Mizuho Securities.

Sales of Spinraza were projected at $16 million in the first quarter and $186 million for the full year but Mizuho biotech analyst Salim Syed wrote to investors earlier this week: “Spinraza beat consensus by a wide margin.”

Both the quarterly revenue and profit figures were higher than expected after the launch of the drug, which is the first under new Chief Executive Officer Michel Vounatsos, who replaced George Scangos at the start of the year.

Biogen said that its overall first-quarter revenue climbed 3 percent over the same quarter last year, to $2.8 billion, and profits for the quarter saw a 7 percent increase, to $1.1 billion.

Vounatsos said in a statement: “The value this therapy provides to patients is compelling, and we are working to accelerate patient access globally.”



Featured Articles

Johnson & Johnson: Turning supplier spend into local support

Johnson & Johnson’s Global Supplier Diversity & Inclusion team is growing spending with social enterprises around the globe to expand its impact

Seasonal Affective Disorder’s impact on health & solutions

Dr Ravi Gill & Dr. Naomi Newman-Beinart discuss Seasonal Affective Disorder and its treatments, from vitamin D spray to light therapy

CGI teams up with Totalmobile for digital healthcare service

CGI is driving efficiency in healthcare. Hear from Helena Jochberger, at Manufacturing Digital LIVE, a free virtual event on Wednesday 6th December 2023

Deloitte: generative AI can improve access to healthcare

Technology & AI

Wipro & NVIDIA’s revolutionary healthcare uses generative AI


Healthtech platform CoverSelf extends seed round to US$8.2m

Technology & AI